Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Philadelphia Chromosome and TP53[original query] |
---|
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010 1 115 (14): 2882-90. Thoennissen Nils H, Krug Utz O, Lee Dhong Hyun Tony, Kawamata Norihiko, Iwanski Gabriela B, Lasho Terra, Weiss Tamara, Nowak Daniel, Koren-Michowitz Maya, Kato Motohiro, Sanada Masashi, Shih Lee-Yung, Nagler Arnon, Raynaud Sophie D, Müller-Tidow Carsten, Mesa Ruben, Haferlach Torsten, Gilliland D Gary, Tefferi Ayalew, Ogawa Seishi, Koeffler H Phill |
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 2017 Oct 123 (19): 3717-3724. Kanagal-Shamanna Rashmi, Jain Preetesh, Takahashi Koichi, Short Nicholas J, Tang Guilin, Issa Ghayas C, Ravandi Farhad, Garcia-Manero Guillermo, Yin Cameron C, Luthra Rajyalakshmi, Patel Keyur P, Khoury Joseph D, Montalban-Bravo Guillermo, Sasaki Koji, Kadia Tapan M, Borthakur Gautam, Konopleva Marina, Jain Nitin, Garris Rebecca, Pierce Sherry, Wierda William, Estrov Zeev, Cortes Jorge, O'Brien Susan, Kantarjian Hagop M, Jabbour Eli |
RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer medicine 2019 Dec . Sakhdari Ali, Thakral Beenu, Loghavi Sanam, Kanagal-Shamanna Rashmi, Yin C Cameron, Zuo Zhuang, Routbort Mark J, Luthra Rajyalakshmi, Medeiros L Jeffrey, Wang Sa A, Patel Keyur P, Ok Chi You |
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up. British journal of haematology 2021 Jul . Romzova Marianna, Smitalova Dagmar, Hynst Jakub, Tom Nikola, Loja Tomas, Herudkova Zdenka, Jurcek Tomas, Stejskal Lukas, Zackova Daniela, Mayer Jiri, Racil Zdenek, Culen Mart |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: